10x Genomics (NASDAQ:TXG) Stock Rating Lowered by Leerink Partnrs

Leerink Partnrs lowered shares of 10x Genomics (NASDAQ:TXG) from a strong-buy rating to a hold rating in a research report report published on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for 10x Genomics’ Q1 2026 earnings at ($0.35) EPS.

A number of other research analysts have also recently commented on the company. Leerink Partners cut 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $25.00 to $12.00 in a research report on Thursday. Canaccord Genuity Group dropped their target price on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday. Barclays dropped their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday. UBS Group cut their target price on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, JPMorgan Chase & Co. cut their price target on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.71.

10x Genomics Price Performance

TXG opened at $11.94 on Thursday. The firm’s fifty day moving average price is $14.75 and its two-hundred day moving average price is $17.43. 10x Genomics has a 1 year low of $10.80 and a 1 year high of $51.22. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -7.80 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. As a group, equities analysts anticipate that 10x Genomics will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TXG. Assenagon Asset Management S.A. bought a new position in shares of 10x Genomics during the fourth quarter valued at approximately $26,308,000. ARK Investment Management LLC increased its holdings in 10x Genomics by 15.4% in the 3rd quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock worth $242,743,000 after buying an additional 1,436,582 shares in the last quarter. Point72 Asset Management L.P. bought a new position in 10x Genomics during the third quarter valued at approximately $27,778,000. SVB Wealth LLC bought a new stake in shares of 10x Genomics during the 4th quarter valued at about $7,505,000. Finally, Trexquant Investment LP grew its position in 10x Genomics by 196.2% during the fourth quarter. Trexquant Investment LP now owns 594,611 shares of the company’s stock valued at $8,539,000 after buying an additional 393,854 shares during the period. Hedge funds and other institutional investors own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.